Growth Hormone Biotech Ascendis Raises $108M In IPO
Growth hormone treatment developer Ascendis Pharma A/S raised $108 million in its initial public offering on Wednesday by selling 6 million shares at $18 apiece, marking the latest in a flurry...To view the full article, register now.
Already a subscriber? Click here to view full article